-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Review: Biomea Fusion (NASDAQ:BMEA) Vs. Amylyx Pharmaceuticals (NASDAQ:AMLX)
Head-To-Head Review: Biomea Fusion (NASDAQ:BMEA) Vs. Amylyx Pharmaceuticals (NASDAQ:AMLX)
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) and Biomea Fusion (NASDAQ:BMEA – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Profitability
This table compares Amylyx Pharmaceuticals and Biomea Fusion's net margins, return on equity and return on assets.
Get Amylyx Pharmaceuticals alerts:| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -172.54% | -93.56% |
| Biomea Fusion | N/A | -45.62% | -42.69% |
Earnings and Valuation
This table compares Amylyx Pharmaceuticals and Biomea Fusion's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $280,000.00 | 8,670.59 | -$87.93 million | N/A | N/A |
| Biomea Fusion | N/A | N/A | -$41.57 million | ($2.44) | -3.91 |
Institutional & Insider Ownership
70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Biomea Fusion shares are owned by institutional investors. 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 45.7% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Amylyx Pharmaceuticals and Biomea Fusion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Biomea Fusion | 0 | 0 | 2 | 0 | 3.00 |
Amylyx Pharmaceuticals currently has a consensus price target of $48.20, indicating a potential upside of 31.55%. Biomea Fusion has a consensus price target of $25.00, indicating a potential upside of 162.33%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Amylyx Pharmaceuticals.
Summary
Biomea Fusion beats Amylyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About Amylyx Pharmaceuticals
(Get Rating)
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Biomea Fusion
(Get Rating)
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) and Biomea Fusion (NASDAQ:BMEA – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
阿米利克斯製藥（NASDAQ：AMLX — 獲取評級）和生物群聚變（NASDAQ：BMEA-獲取評級）都是醫療公司，但哪個是更好的股票？我們將根據兩家企業的機構所有權，風險，估值，收益，分析師建議，盈利能力和股息的實力進行比較。
Profitability
盈利
This table compares Amylyx Pharmaceuticals and Biomea Fusion's net margins, return on equity and return on assets.
此表格比較 Amylyx 製藥和生物塔融合的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -172.54% | -93.56% |
| Biomea Fusion | N/A | -45.62% | -42.69% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 阿米利克斯制药 | N/A | -172.54% | -93.56% |
| 生物群融合 | N/A | -45.62% | -42.69% |
Earnings and Valuation
收益及估值
This table compares Amylyx Pharmaceuticals and Biomea Fusion's top-line revenue, earnings per share and valuation.
該表比較了 Alylyx 製藥和生物群島融合的頂級收入，每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $280,000.00 | 8,670.59 | -$87.93 million | N/A | N/A |
| Biomea Fusion | N/A | N/A | -$41.57 million | ($2.44) | -3.91 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 阿米利克斯制药 | 280,000.00 | 8,670.59 | -87.93 萬美元 | N/A | N/A |
| 生物群融合 | N/A | N/A | -4 億一百五十七萬元 | (二百四十四元) | -3.91 |
Institutional & Insider Ownership
機構和內幕所有權
70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Biomea Fusion shares are owned by institutional investors. 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 45.7% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
奧米利克斯製藥的 70.6％ 股份由機構投資者擁有。相比之下，50.3％ 的生物群融合股份由機構投資者擁有。12.7％ 的 Amylyx 製藥股份由公司內部人員擁有。相比之下，45.7％ 的生物群融合股份由公司內部人士擁有。強大的機構所有權表明，對沖基金，大型資金經理和捐贈基金認為，從長期來看，公司的表現將優於市場。
Analyst Ratings
分析師評級
This is a summary of current ratings and target prices for Amylyx Pharmaceuticals and Biomea Fusion, as reported by MarketBeat.
這是阿米利克斯製藥和生物群融合的當前評分和目標價格的摘要，如 MarketBeat 的報告。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Biomea Fusion | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 阿米利克斯制药 | 0 | 1 | 4 | 0 | 2.80 |
| 生物群融合 | 0 | 0 | 2 | 0 | 3.00 |
Amylyx Pharmaceuticals currently has a consensus price target of $48.20, indicating a potential upside of 31.55%. Biomea Fusion has a consensus price target of $25.00, indicating a potential upside of 162.33%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Amylyx Pharmaceuticals.
阿米利克斯製藥目前的共識價格目標為 48.20 美元，表明潛在的上行空間為 31.55％。生物群融合的共識價格目標為 25.00 美元，表明潛在的上行空間為 162.33％。鑑於生物協會融合的更強大的共識評級和更高的可能上漲，分析師清楚地認為，生物群融合比 Amylyx 製藥更有利。
Summary
摘要
Biomea Fusion beats Amylyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
生物群島融合擊敗阿米利克斯製藥的 6 9 因素之間的兩個股票之間的比較。
About Amylyx Pharmaceuticals
關於阿米利克斯製藥
(Get Rating)
(取得評分)
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx 製藥公司是一家臨床階段的生物製藥公司，致力於開發肌萎縮性側索硬化症（ALS）和其他神經退行性疾病的各種療法。公司的產品線包括 AMX0035，一種由苯基丁酸鈉和牛磺二醇組成的雙 UPR-BAX 凋亡抑製劑，用於治療肌萎縮性側索硬化症。它還正在為其他神經退行性疾病開發 AMX0035。該公司成立於 2013 年，總部位於麻薩諸塞州劍橋。
About Biomea Fusion
關於生物群融合
(Get Rating)
(取得評分)
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Liomea Fusion, Inc. 是一家生物製藥公司，專注於共價小分子藥物的發現和開發，用於治療基因定義癌症和代謝性疾病的患者。它的主要候選產品是 BMF-219，一種口服生物可利用，強效和選擇性的選擇性共價抑製劑 Menin，這是多種癌症中致癌信號傳輸的轉錄調節劑。該公司成立於 2017 年，總部位於加利福尼亞州紅木城。
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Alyx 藥品的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Amylyx 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧